�y��vlog

Because PAR1 -- the protein activated by S. aureus -- is involved in blood-clotting, researchers wanted to see whether an already approved anticlotting drug that blocks PAR1 would stop itch.

Each will be randomly assigned one of three potential therapies: an anticlotting drug called rivaroxaban, an anti-inflammatory called colchicine, or a pair of antihistamines, famotidine and loratadine.

The results also hint at a surprising role for the liver and anticlotting systems in these effects and possibly point the way to a futuristic scenario of exercise in a pill—or perhaps a plasma injection.

They found increased levels of anticlotting proteins, including one called “clusterin,” which helps to clear cells of debris.

Despite similar anticlotting protein profiles between the sexes, the females showed more variability.